Malaria - Pipeline Review, H2 2017

  • ID: 4426902
  • Report
  • 372 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 4SC AG
  • Cadila Healthcare Ltd
  • Fosun International Ltd
  • Immunovaccine Inc
  • Merck KGaA
  • PaxVax Inc
  • MORE
Malaria - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Malaria - Pipeline Review, H2 2017, provides an overview of the Malaria (Infectious Disease) pipeline landscape.

Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria and pregnant women and their unborn children. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea and vomiting. Treatment includes anti-malarial medicines and healthy lifestyle.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Malaria - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Malaria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malaria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Malaria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 13, 13, 57 and 29 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 12, 46 and 42 molecules, respectively.

Malaria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Malaria (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Malaria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Malaria (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Malaria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Malaria (Infectious Disease).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Malaria (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Malaria (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4SC AG
  • Cadila Healthcare Ltd
  • Fosun International Ltd
  • Immunovaccine Inc
  • Merck KGaA
  • PaxVax Inc
  • MORE
Introduction

Malaria - Overview

Malaria - Therapeutics Development

Malaria - Therapeutics Assessment

Malaria - Companies Involved in Therapeutics Development

Malaria - Drug Profiles

Malaria - Dormant Projects

Malaria - Discontinued Products

Malaria - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Malaria, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Malaria - Pipeline by 4SC AG, H2 2017

Malaria - Pipeline by AbbVie Inc, H2 2017

Malaria - Pipeline by Actelion Pharmaceuticals Ltd, H2 2017

Malaria - Pipeline by Agilvax Inc, H2 2017

Malaria - Pipeline by Akshaya Bio Inc, H2 2017

Malaria - Pipeline by Allergy Therapeutics Plc, H2 2017

Malaria - Pipeline by Altimmune Inc, H2 2017

Malaria - Pipeline by Amura Holdings Ltd, H2 2017

Malaria - Pipeline by Artificial Cell Technologies Inc, H2 2017

Malaria - Pipeline by AstraZeneca Plc, H2 2017

Malaria - Pipeline by Bharat Biotech International Ltd, H2 2017

Malaria - Pipeline by Cadila Healthcare Ltd, H2 2017

Malaria - Pipeline by Carna Biosciences Inc, H2 2017

Malaria - Pipeline by CEL-SCI Corp, H2 2017

Malaria - Pipeline by Celgene Corp, H2 2017

Malaria - Pipeline by Cilian AG, H2 2017

Malaria - Pipeline by Daiichi Sankyo Co Ltd, H2 2017

Malaria - Pipeline by DesignMedix Inc, H2 2017

Malaria - Pipeline by Eisai Co Ltd, H2 2017

Malaria - Pipeline by Expres2ion Biotechnologies ApS, H2 2017

Malaria - Pipeline by Fosun International Ltd, H2 2017

Malaria - Pipeline by GenVec Inc, H2 2017

Malaria - Pipeline by Genzyme Corp, H2 2017

Malaria - Pipeline by GeoVax Labs Inc, H2 2017

Malaria - Pipeline by GlaxoSmithKline Plc, H2 2017

Malaria - Pipeline by Hager Biosciences LLC, H2 2017

Malaria - Pipeline by iBio Inc, H2 2017

Malaria - Pipeline by Ichor Medical Systems Inc, H2 2017

Malaria - Pipeline by Immunovaccine Inc, H2 2017

Malaria - Pipeline by IPCA Laboratories Ltd, H2 2017

Malaria - Pipeline by Jomaa Pharma GmbH, H2 2017

Malaria - Pipeline by Kancera AB, H2 2017

Malaria - Pipeline by Kymab Ltd, H2 2017

Malaria - Pipeline by Lipocure Ltd, H2 2017

Malaria - Pipeline by Lipotek Pty Ltd, H2 2017

Malaria - Pipeline by LondonPharma Ltd, H2 2017

Malaria - Pipeline by Marinomed Biotechnologie GmbH, H2 2017

Malaria - Pipeline by Merck KGaA, H2 2017

Malaria - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2017

Malaria - Pipeline by Microbiotix Inc, H2 2017

Malaria - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017

Malaria - Pipeline by Mucosis BV (Inactive), H2 2017

Malaria - Pipeline by Mymetics Corp, H2 2017

Malaria - Pipeline by Nobelpharma Co Ltd, H2 2017

Malaria - Pipeline by Novartis AG, H2 2017

Malaria - Pipeline by Osivax SAS, H2 2017

Malaria - Pipeline by Otsuka Holdings Co Ltd, H2 2017

Malaria - Pipeline by PaxVax Inc, H2 2017

Malaria - Pipeline by Pfizer Inc, H2 2017

Malaria - Pipeline by Protein Potential LLC, H2 2017

Malaria - Pipeline by Rodos BioTarget GmbH, H2 2017

Malaria - Pipeline by Sanaria Inc, H2 2017

Malaria - Pipeline by Sanofi, H2 2017

Malaria - Pipeline by SBI Pharmaceuticals Co Ltd, H2 2017

Malaria - Pipeline by Selecta Biosciences Inc, H2 2017

Malaria - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017

Malaria - Pipeline by Theravectys SA, H2 2017

Malaria - Pipeline by Titan Pharmaceuticals Inc, H2 2017

Malaria - Pipeline by Toyama Chemical Co Ltd, H2 2017

Malaria - Pipeline by VLP Biotech Inc, H2 2017

Malaria - Pipeline by VLP Therapeutics LLC, H2 2017

Malaria - Dormant Projects, H2 2017

Malaria - Discontinued Products, H2 2017

List of Figures

Number of Products under Development for Malaria, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 4SC AG
  • AbbVie Inc
  • Actelion Pharmaceuticals Ltd
  • Agilvax Inc
  • Akshaya Bio Inc
  • Allergy Therapeutics Plc
  • Altimmune Inc
  • Amura Holdings Ltd
  • Artificial Cell Technologies Inc
  • AstraZeneca Plc
  • Bharat Biotech International Ltd
  • Cadila Healthcare Ltd
  • Carna Biosciences Inc
  • CEL-SCI Corp
  • Celgene Corp
  • Cilian AG
  • Daiichi Sankyo Co Ltd
  • DesignMedix Inc
  • Eisai Co Ltd
  • Expres2ion Biotechnologies ApS
  • Fosun International Ltd
  • GenVec Inc
  • Genzyme Corp
  • GeoVax Labs Inc
  • GlaxoSmithKline Plc
  • Hager Biosciences LLC
  • iBio Inc
  • Ichor Medical Systems Inc
  • Immunovaccine Inc
  • IPCA Laboratories Ltd
  • Jomaa Pharma GmbH
  • Kancera AB
  • Kymab Ltd
  • Lipocure Ltd
  • Lipotek Pty Ltd
  • LondonPharma Ltd
  • Marinomed Biotechnologie GmbH
  • Merck KGaA
  • MerLion Pharmaceuticals Pte Ltd
  • Microbiotix Inc
  • Mitsubishi Tanabe Pharma Corp
  • Mucosis BV (Inactive)
  • Mymetics Corp
  • Nobelpharma Co Ltd
  • Novartis AG
  • Osivax SAS
  • Otsuka Holdings Co Ltd
  • PaxVax Inc
  • Pfizer Inc
  • Protein Potential LLC
  • Rodos BioTarget GmbH
  • Sanaria Inc
  • Sanofi
  • SBI Pharmaceuticals Co Ltd
  • Selecta Biosciences Inc
  • Takeda Pharmaceutical Co Ltd
  • Theravectys SA
  • Titan Pharmaceuticals Inc
  • Toyama Chemical Co Ltd
  • VLP Biotech Inc
  • VLP Therapeutics LLC
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll